Detalhe da pesquisa
1.
In situ tumour arrays reveal early environmental control of cancer immunity.
Nature
; 618(7966): 827-833, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37258670
2.
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center.
Int J Cancer
; 148(10): 2502-2511, 2021 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231298
3.
From presentation to paper: Gender disparities in oncological research.
Int J Cancer
; 146(11): 3011-3021, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31472016
4.
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Cancer
; 126(22): 4936-4947, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32870522
5.
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
Br J Cancer
; 123(10): 1481-1489, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32839491
6.
Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial.
Invest New Drugs
; 38(6): 1879-1887, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383099
7.
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Invest New Drugs
; 37(4): 674-683, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30411218
8.
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.
Invest New Drugs
; 37(4): 693-701, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30547316
9.
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
BMC Cancer
; 19(1): 167, 2019 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30791889
10.
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
Invest New Drugs
; 36(6): 1044-1059, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808308
11.
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
J Neurooncol
; 130(1): 181-192, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27502603
12.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Lancet Oncol
; 16(8): 949-56, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26179200
13.
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.
Oncologist
; 25(2): e391-e395, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043780
14.
Emerging new anticancer therapies in 2013.
Curr Opin Oncol
; 26(3): 357-62, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709976
15.
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Sci Transl Med
; 16(731): eadd1834, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266104
16.
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Clin Cancer Res
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630781
17.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Nat Commun
; 15(1): 1700, 2024 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402224
18.
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials.
Onkologie
; 36(6): 357-62, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23774150
19.
Distant antimetastatic effect of enterotropic colon cancer-derived α4ß7+CD8+ T cells.
Sci Immunol
; 8(84): eadg8841, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289857
20.
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
J Clin Oncol
; 41(15): 2724-2735, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780608